Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Summary
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Arms & interventions
- DrugVisugromab (CTL-002)
High dose
- DrugPlacebo
IV infusion
- DrugVisugromab (CTL-002)
Medium dose
- DrugVisugromab (CTL-002)
Low dose
Outcome measures
Primary
Change from baseline in body weight at 12 weeks
Time frame: 12 weeks
Change from baseline in appetite at 12 weeks
Measured on the 5-item anorexia subscale of the Functional Assessment of Anorexia/Cachexia Therapy instrument (minimum score 0, maximum 20; higher is better outcome)
Time frame: 12 weeks
Eligibility criteria
Study locations (6)
Clermont Oncology Center
Clermont, Florida, 34711
Mid Florida Hematology and Oncology Centers
Orange City, Florida, 32763
Cleveland Clinic Avon Hospital
Avon, Ohio, 44011
Cleveland Clinic (Main Campus)
Cleveland, Ohio, 44195
Cleveland Clinic Fairview Hospital
Fairview, Ohio, 44111
Cleveland Clinic Hillcrest Hospital
Mayfield Heights, Ohio, 44124